Rheumatology (Oxford).2023;kead181. doi 10.1093/rheumatology/kead181.
Results from the 52-week phase 3 EXCEED study showed that secukinumab and adalimumab both display similar efficacy in time to resolution of enthesitis, in patients with PsA, irrespective of baseline enthesitis severity and individual site distribution.
Clinical enthesitis occurs in around 35%–50% of patients with PsA. These patients experience a significantly higher disease burden and greater erosive damage than patients without enthesitis. The resolution of enthesitis is an important clinical outcome and can be used to assess treatment responses among patients with PsA and has been associated with improvements in other clinical outcomes.